Cancer Chemotherapy and Pharmacology

, Volume 58, Supplement 1, pp 49–53

Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm

Article

Abstract

The small molecule BCR-ABL-selective kinase inhibitor imatinib is the single most effective medical therapy for the treatment of chronic myeloid leukemia (CML). Although imatinib is highly effective initially and generally well tolerated, for patients who undergo relapse or disease progression few effective therapeutic options exist. Studies have demonstrated that the principal mechanisms of imatinib resistance are BCR-ABL kinase domain point mutation and over-expression. Two novel, potent BCR-ABL inhibitors that harbor promising preclinical activity are undergoing clinical trial evaluation. These agents, dasatinib (BMS-354825) and nilotinib (AMN107), effectively inhibit the activity of nearly all imatinib-resistant BCR-ABL kinase domain mutant forms tested in vitro. Notably, however, neither of these compounds is effective against the imatinib-resistant BCR-ABL/T315I mutation. Early clinical evidence suggests that the T315I mutation might drive the majority of cases who acquire resistance to these second-generation agents. Preclinical efforts to identify an inhibitor of the BCR-ABL/T315I mutation have resulted in demonstration that the Aurora kinase inhibitor VX-680 can bind and inhibit the kinase domain of BCR-ABL/T315I.

Keywords

BCR-ABL CML Imatinib Dasatinib Tyrosine kinase inhibitor Resistance 

References

  1. 1.
    Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C, Niederwieser D, Druker BJ, Deininger MWN (2004) High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 5:55–60PubMedCrossRefGoogle Scholar
  2. 2.
    Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472–3475PubMedCrossRefGoogle Scholar
  3. 3.
    Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J (2002) BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet 139:30–33PubMedCrossRefGoogle Scholar
  4. 4.
    Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH III, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102:11011–11016PubMedCrossRefGoogle Scholar
  5. 5.
    Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW (2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101:4611–4614PubMedCrossRefGoogle Scholar
  6. 6.
    Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690–698PubMedCrossRefGoogle Scholar
  7. 7.
    Gadzicki D, von Neuhoff N, Steinemann D, Just M, Busche G, Kreipe H, Wilkens L, Schlegelberger B (2005) BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer Genet Cytogenet 159:164–167PubMedCrossRefGoogle Scholar
  8. 8.
    Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Nagesh Rao P, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880PubMedCrossRefGoogle Scholar
  9. 9.
    Guilhot F (2004) Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: update from the IRIS Study (abstract 21). Blood 104:11Google Scholar
  10. 10.
    Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NCP, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190–2196PubMedCrossRefGoogle Scholar
  11. 11.
    Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG (2002) Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359:481–486PubMedCrossRefGoogle Scholar
  12. 12.
    Kantarjian H, Ottmann O, Cortes J, Wassmann B, Jones D, Hochhaus A, Alland L, Dugan M, Albitar M, Giles F (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML) (abstract 3014). J Clin Oncol 23 (Suppl):195SGoogle Scholar
  13. 13.
    Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gamabcorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652PubMedCrossRefGoogle Scholar
  14. 14.
    Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792PubMedCrossRefGoogle Scholar
  15. 15.
    Morel F, Le Bris M-J, Herry A, Le Calvez G, Marion V, Abgrall J-F, Berthou C, De Braekeleer M (2005) Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur J Haematol 70:235–239CrossRefGoogle Scholar
  16. 16.
    O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MWN, Druker BJ (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500–4505PubMedCrossRefGoogle Scholar
  17. 17.
    Ottmann O, Giles F, Wassmann B, Hochhaus A, Rae P, Beran M, Albitar M, Alland L, Dugan M, Kantarjian H (2005) Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant bcr-abl positive lymphoid malignancies (abstract 3015). J Clin Oncol 23(Suppl):195SGoogle Scholar
  18. 18.
    Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e17PubMedCrossRefGoogle Scholar
  19. 19.
    Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai J-L, Philippe N, Facon T, Fenaux P, Preudhomme C (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014–1018PubMedCrossRefGoogle Scholar
  20. 20.
    Sawyers CL, Shah NP, Kantarjian HM, Cortes J, Paquette R, Nicoll J, Bai SA, Clark E, Decillis AP, Talpaz M (2005) A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML): results from CA180002 (abstract 6520) J Clin Oncol 23 (Suppl)Google Scholar
  21. 21.
    Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938–1942PubMedCrossRefGoogle Scholar
  22. 22.
    Shah NP, Nicoll JM, Nagar B, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117–125PubMedCrossRefGoogle Scholar
  23. 23.
    Shah N, Sawyers PCL, Kantarjian HM, Donato N, Nicoll J, Cortes J, Paquette R, Huang F, Clark E, Talpaz M (2005) Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph + ALL) (abstract 6521) J Clin Oncol 23(Suppl)565SGoogle Scholar
  24. 24.
    Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399–401PubMedCrossRefGoogle Scholar
  25. 25.
    Talpaz M, Kantarjian HM, Paquette R, Shah N, Cortes J, Nicoll J, Bai SA, Huang F, Decillis AP, Sawyers CL (2005) A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): results from CA180002 (abstract 6519). J Clin Oncol 23(Suppl):64SGoogle Scholar
  26. 26.
    von Bubnoff N, Schneller F, Peschel C, Duyster J (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359:487–491CrossRefGoogle Scholar
  27. 27.
    Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GO, Callahan L, Catley L, Cavazza C, Mohammed A, Neuberg D, Wright RD, Gilliland DG, Griffin JD (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129–141PubMedCrossRefGoogle Scholar
  28. 28.
    Yamamoto M, Kakihana K, Kurosu T, Murakami N, Miura O (2005) Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet 157:104–108PubMedCrossRefGoogle Scholar
  29. 29.
    Young MA, Shah NP, Chao LH, Seeliger M, Milznov ZV, Biggs WH 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J (2006) Structure of the kinase domain of an imatinib-resistant ABL mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 66:1007–1014PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Division of Hematology/OncologyUCSF School of MedicineSan FranciscoUSA

Personalised recommendations